Search Results - "Musto, Kaylinn"

Effect of β-hydroxy-β-methylbutyrate (HMB) on muscle strength in older men with prostate cancer (Pca) started on androgen deprivation therapy (ADT): Preliminary results of an open-label, randomized trial by Bylow, Kathryn A., Kilari, Deepak, Riese, Matthew John, Burfeind, John, Stolley, Melinda, Prost, Robert W, Musto, Kaylinn, Neilson, Raquel, Szabo, Aniko, Thomas, James P., Ng, Alexander V.

“…Abstract only 258 Background: ADT causes muscle weakness and wasting within 3 months (mo), causing older men on ADT to experience functional impairments and…”
Get full text

A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Tolerability and geriatric asssessment (GA) results by Zittel, Jason, Fung, Chunkit, Babu, Dilip Sankar, Guancial, Elizabeth A., Sahasrabudhe, Deepak M., Bylow, Kathryn A., Burfeind, John D., Musto, Kaylinn, Wang, Bokai, Patil, Amita, Messing, Edward M., Mohile, Supriya Gupta, Kilari, Deepak

“…Abstract only e16518 Background: Older men are at a high risk for adverse events (AEs) from androgen deprivation therapy (ADT). In this phase II study, we…”
Get full text

A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa) by Kilari, Deepak, Guancial, Elizabeth A., Sahasrabudhe, Deepak M., Bylow, Kathryn A., Burfeind, John D., Musto, Kaylinn, Feng, Changyong, Messing, Edward M., Mohile, Supriya Gupta, Fung, Chunkit

“…Abstract only 179 Background: Older men are at a high risk for adverse events (AEs) from androgen deprivation therapy (ADT). In prior studies, peripheral…”
Get full text